GlassScriptPhysician profile
Robert Leo Jimenez
NPI 1083713614
$7,297.38
in general payments reported to CMS, 2019-2025
16 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $1,058 · 2021: $1,001 · 2022: $1,056 · 2023: $1,225 · 2024: $1,800 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $73.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.73 |
| Education | $73.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,041.18 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,013.12 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $572.26 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $526.35 | 2019-2024 | Aristada, Lybalvi |
| Allergan, INC. | $467.63 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $393.70 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $384.33 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $345.30 | 2019-2022 | |
| Axsome Therapeutics, INC. | $170.13 | 2023-2024 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $111.96 | 2020-2023 | Trintellix |
| Lundbeck LLC | $98.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $68.66 | 2019-2020 | |
| Indivior INC. | $43.40 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $34.99 | 2023-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $13.75 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.